WithdrawnPhase 1

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Lead sponsor

Methodist Health System

Asset

Semaglutide

GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight, PCOS

Eligibility highlights

•BMI ≥30•Female

Primary endpoints

•Number of appropriate weekly dose•Number of days on therapy

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06222437

Org study ID046.OBG.2023.D

Timeline

Milestones

Study first posted2024-01-24actual

Last update posted2026-03-23actual

Study start2026-02estimated (month precision)

Primary completion2026-02estimated (month precision)

Study completion2027-02estimated (month precision)

Assets

Investigational agents

Semaglutide

Who this study enrolls

Obesity / overweightPCOS

Who can enroll

Minimum age18 Years

Maximum age45 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•Age 18-45

•Body mass index(BMI) > 30

•Diagnosis of PCOS

•Normal thyroid stimulating hormone, prolactin, follicle-stimulating hormone (FSH), estradiol, and normal progesterone

Exclusion criteria

•Medications excluded: any hormone-containing contraceptive - oral contraceptive pills, Progesterone-only pill, depo-provera, oral provera, progesterone-containing intrauterine contraceptive device

•Letrozole, clomiphene citrate, FSH therapy

•Androgen receptor blockers

•5α reductase inhibitors

•Insulin

•Hysterectomy

•Endometrial ablation

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Weight & body composition

Other clinical outcomes

Weight & body composition

1 endpoint

Secondary/protocol endpoint

measure the Weight in kilograms

Time frame:4 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Safety / tolerability / PK

2 endpoints

Primary/protocol endpoint

Number of appropriate weekly dose

Time frame:4 weeks

descriptive

Primary/protocol endpoint

Number of days on therapy

Time frame:4 weeks

descriptive

Other clinical outcomes

1 endpoint

Secondary/protocol endpoint/low confidence

Numbers of days with exercise changes

Time frame:4 weeks

event count, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.